ABSTRACT
Gardasil, a vaccine against human papillomavirus (HPV), recently became available in the United States for use in girls and women 9 to 26 years of age. A second HPV vaccine, Cervarix, is under development. These vaccines constitute the most significant development in cervical cancer prevention in the last 60 years, having the potential to reduce the incidence of cervical cancer by up to 70%.
Footnotes
↵* Dr. Kahn has disclosed that she has received a consulting fee from the SciMed and Merck corporations for editing a journal supplement on HPV vaccines.
- © 2006 The Cleveland Clinic Foundation. All Rights Reserved.